Personalized mRNA Vaccine Shows Lasting Survival in Pancreatic Cancer Trial

52 articles · Updated · ScienceAlert · Apr 23

A personalized mRNA vaccine for pancreatic cancer has shown promising long-term results in a small phase 1 clinical trial.
Seven of eight patients who responded to the vaccine remain alive six years after treatment, significantly exceeding typical survival rates.
The vaccine, tailored from each patient’s tumor, may offer new hope for one of the deadliest cancers, with larger trials now underway.

Can a two-month custom vaccine process ever become a mainstream cancer treatment?

Beyond pancreatic cancer, which deadly disease will this mRNA technology target next?

Will the U.S. fall behind in the cancer vaccine race after its major funding cuts?

Could 'off-the-shelf' vaccines make this personalized approach obsolete before it launches?

Why did this breakthrough vaccine fail for half the patients in the trial?